Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes

Journal of Neuroimmunology

Volumn 136, Issue 1-2, 2003, Pages 46-53

  Avolio, Carlo ^a   Ruggieri, Maddalena ^b   Giuliani, Fabrizio ^b   Liuzzi, Grazia Maria ^b   Leante, Rosaria ^b   Riccio, Paolo ^c   Livrea, Paolo ^b   Trojano, Maria ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Matrix metalloproteinases; Multiple sclerosis; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CHRONIC DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; EVALUATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELAPSE;

EID: 0037333750     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00006-7     Document Type: Article

References (53)

1. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredriksen S., Gallo P., Grimaldi L.M., Gronning M., Keir G., Lamers K., Link H., Magalhaes A., Massaro A.S., Ohman S., Reiber H., Ronnback L., Schluep M., Schuller E., Sindic C.J.M., Thompson E.J., Trojano M., Wurster U. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry. 57:1994;897-902.
2. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23:1997;406-415.
3. Bever C.H., Rosenberg G.A. Matrix metalloproteinases in multiple sclerosis. Targets of therapy or markers of injury. Neurology. 53:1999;1380-1381.
4. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 1477:2000;267-283.
5. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C.C., Adams S.E., Gearing A.J.H. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:1997;155-161.
6. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
7. Dubois D., D'Hooghe M.B., De Lepeleire K., Ketelaer P., Opdenakker G., Carton H. Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Mult. Scler. 4:1998;74-78.
8. Filippi M., Wolinsky J.S., Sormani M.P., Comi G. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology. 56:2001;422-423.
9. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to Interferon β therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50:2001;443-451.
10. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
11. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94:1994;2177-2182.
12. Hartung H.P., Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107:2000;140-147.
13. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
14. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169:2002;2643-2647.
15. Johnston J.B., Zhang K., Silva C., Shalinsky D.R., Conant K., Ni W., Corbett D., Yong V.W., Power C. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitor. Ann. Neurol. 49:2001;230-241.
16. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., Gearing A.J., Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 121:1998;159-166.
17. Kieseier B.C., Seifert T., Giovannoni G., Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology. 53:1999;20-25.
18. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J. Neuroimmunol. 84:1998;143-150.
19. Kouwenhoven M., Ozenci V., Gomes A., Yarilin D., Giedraitis V., Press R., Link H. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J. Autoimmun. 16:2001;463-470.
20. Kouwenhoven M., Ozenci V., Tjernlund A., Pashenkov M., Homman M., Press R., Link H. Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J. Neuroimmunol. 126:2002;161-171.
21. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 33:1983;1444-1452.
22. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 122:1999;191-197.
23. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
24. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
25. Leppert D., Leib S.L., Grygar C., Miller K.M., Schaad U.B., Hollander G.A. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin. Infect. Dis. 31:2000;80-84.
26. Leppert D., Lindberg R.L.P., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brains Res. Rev. 36:2001;249-257.
27. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J. Neuroimmunol. 99:1999;19-26.
28. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J.H., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
29. Lindberg R.L.P., De Groot C.J.A., Montagne L., Freitag P., van der Valk P., Kappos L., Leppert D. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain. 124:2001;1743-1753.
30. Link H., Tibbling G. Principles of albumin and IgG analyses in neurological disorders: III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 37:1977;397-401.
31. Liuzzi G.M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., Riccio P. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult. Scler. 8:2002;222-228.
32. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology. 46:1996;907-911.
33. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
34. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
35. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50:2001;121-127.
36. Neuhaus O., Farina C., Wekerle H., Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 56:2001;702-708.
37. Newman T.A., Wolley S.T., Hughes P.M., Sibson N.R., Anthony D.C., Perry V.H. T-cell and macrophage-mediated axon damage in the absence of CNS-specific immune response: involvement of metalloproteinases. Brain. 124:2001;2203-2214.
38. Ogata Y., Itoh Y., Nagase H. Steps involved in activation of pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinase-1 complex by 4-aminophenylmercuric acetate and proteinases. J. Biol. Chem. 270:1995;18506-18511.
39. Ozenci V., Rinaldi L., Teleshova N., Matusevicius D., Kivisakk P., Kouwendhoven M., Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 12:1999;297-303.
40. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:1994;55-63.
41. Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe-Seyler. 376:1995;345-355.
42. Rosenberg G.A. Matrix metalloproteinase in multiple sclerosis: it is time for a treatment trial? Ann. Neurol. 50:2001;431-433.
43. Rosenberg G.A., Dencoff J.E., Correa N., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 46:1996;1626-1632.
44. Shapiro S.D., Fliszar C.J., Broekelmann T.J., Mecham R.P., Senior R.M., Welgus H.G. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J. Biol. Chem. 270:1995;6351-6356.
45. Smith M.E., Eller N.F., McFarland H.F., Racke M.K., Raine C.S. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am. J. Pathol. 155:1999;1147-1161.
46. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
47. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders: Part I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37:1977;385-390.
48. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., Santacroce M.P., Paolicelli D., Giuliani F., Riccio P., Livrea P. Changes of serum ICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology. 53:1999;1402-1408.
49. Trojano M., Liguori M., Zimatore G.B., Bugarini R., Avolio C., Paolicelli D., Giulani F., De Robertis F., Marrosu M.G., Livrea P. Age-related disability in multiple sclerosis. Ann. Neurol. 51:2002;475-480.
50. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., Andersson P.-B., Stabler G., Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 53:1999;1397-1401.
51. Yong V.W. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology. 59:2002;802-808.
52. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2:2001;502-511.
53. Yushchenko M., Weber F., Mader M., Scholl U., Maliszewska M., Tumani H., Felgenhauer K., Beuche W. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110:2000;244-251.